Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Zhonghua Wei Chang Wai Ke Za Zhi ; 21(9): 1019-1024, 2018 Sep 25.
Artigo em Chinês | MEDLINE | ID: mdl-30269322

RESUMO

OBJECTIVE: To evaluate the short-term efficacy and safety of neoadjuvant synchronous chemoradiotherapy (paclitaxel plus carboplatin regimen) in stage III adenocarcinoma of esophagogastric junction (AEG). METHODS: Forty cases clinically diagnosed as stage III AEG were prospectively enrolled at the Department of Gastrointestinal Oncology Surgery, the First Affiliated Hospital of Hebei North University from December 2014 to November 2017 and then were randomly divided into paclitaxel plus carboplatin combined with synchronous radiotherapy group(neoadjuvant group) and direct operation group. Inclusion criteria was as follows:(1) AEG was diagnosed by gastroscopic biopsy and III stage was confirmed by ultrasound endoscopy and spiral CT;(2) physical strength score ≥70, and age ≤75 years old; (3) no contraindications of chemoradiotherapy and operation. Exclusion criteria was as follows:(1) patients voluntarily withdrew or refused the treatment;(2) occurrence of severe anaphylaxis; (3) uncontrollable events happened during treatment and treatment was unable to continue;(4) tumor developed obviously during treatment. Preoperative neoadjuvant synchronous chemoradiotherapy used TP regimen: paclitaxel 80 mg/m², drug concentration-time area under curve of carboplatin= 1.5 mg×ml⁻¹×min⁻¹, once per week for 9 weeks; radiotherapy began at the second week, 40 Gy/20 F, completed within 4 weeks. Operative procedure of both groups was radical resection of cardiac cancer(D2). Postoperative chemotherapy regimen was oral Tegafur(Gimeracil and Oteracil potassium). The side effects, diet situation, change of gastroscopic image after treatment in patients of neoadjuvant group were observed and efficacy evaluation of chemotherapy was performed according to solid tumor efficacy evaluation criteria of US National Cancer Institute. Operation-associated parameters, including R0 resection rate, lymph node metastasis, operative mortality and postoperative complications, were compared between two groups. RESULTS: There were no significant differences in baseline information between the two group (all P>0.05). One case in neoadjuvant group was excluded because of perforation at lesion site 7 weeks after chemotherapy. The side effects of 19 cases in neoadjuvant group were mainly alopecia (100%) and marrow inhibition (68.4%), while 3-4 degree side effects were alopecia(8/19,42.1%), leukopenia (3/19, 15.8%) and neutropenia(3/19, 15.8%). Complete remission was observed in 4 cases; partial remission was observed in 13 cases and stable disease in 2 cases, with an objective response rate of 89.5% and a disease control rate of 100%. Before neoadjuvant chemotherapy, 16 cases were difficult to take liquid diet and 3 cases received liquid diet only, while after 12 weeks of neoadjuvant chemotherapy, all the 19 cases received normal diet. Besides, after neoadjuvant chemotherapy, gastroscopic examination showed close healing of cardiac ulcer, disappearance of swelling, and renewal of normal mucosa. Compared to direct operation group, neoadjuvant group had less number of positive lymph node (4.9±3.6 vs. 8.8±2.8, P<0.05) and higher R0 resection rate (94.7% vs. 50.0%, P<0.05). Total number of harvested lymph node was not significantly different between two groups (19.1±2.5 vs. 18.6±7.0, t=0.326, P=0.746). There was no surgical death in either group. One case in direct operation group developed postoperative inflammatory obstruction. No associated complication was found in neoadjuvant group. CONCLUSION: Paclitaxel plus carboplatin combined with synchronous radiotherapy can elevate the R0 resection rate of patients with stage III esophagogastric junction adenocarcinoma, without increasing operative mortality and postoperative complications.


Assuntos
Adenocarcinoma/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Esofágicas/terapia , Junção Esofagogástrica , Terapia Neoadjuvante , Neoplasias Gástricas/terapia , Adenocarcinoma/tratamento farmacológico , Idoso , Carboplatina/administração & dosagem , Quimiorradioterapia , Humanos , Estadiamento de Neoplasias , Paclitaxel/administração & dosagem , Taxa de Sobrevida
2.
Conf Proc IEEE Eng Med Biol Soc ; 2005: 5873-6, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-17281596

RESUMO

In this paper, we propose a non-invasive detection method of lung cancer combined with a sort of virtual SAW gas sensors array and imaging recognition method. A patient's breath goes through an electronic nose with solid phase micro extraction (SPME) and capillary column for pre-concentration and separation of volatile organic compounds (VOCs) respectively, a pair of SAW sensors one coated with a thin Poly-isobutylene (PIB) film is connected to the output of capillary column port for chemical compounds detection. A lung cancer tissues' culture medium study is also proposed for pathology validation. 11 VOCs which are considered as the biomarkers of lung cancer can be detected qualitatively and quantitatively. Finally these 11 VOCs are used to diagnose lung cancer patients in Run Run Shaw hospital by our e-nose with an improved artificial neural network (ANN) algorithm combined with imaging method for pattern recognition.

3.
World J Gastroenterol ; 10(20): 2944-8, 2004 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-15378770

RESUMO

AIM: To investigate the effect of schisandrin B (Sch B) on proliferation and apoptosis of human hepatoma SMMC-7721 cells in vitro and regulation of Hsp70 and Caspases-3, 7, 9 expression by Sch B. METHODS: Human hepatoma cell line SMMC-7721 was cultured and treated with Sch B at various concentrations. Growth suppression was detected with MTT colorimetric assay. Cell apoptosis was confirmed by DNA ladder detection and flow cytometric analysis. The expression of Hsp70, Caspases-3, 7, 9 were analyzed by Western blot analysis. RESULTS: Sch B inhibited the growth of hepatoma SMMC-7721 cells in a dose-dependent manner, leading to a 50% decrease in cell number (LC50) value of 23.50 mg/L. Treatment with Sch B resulted in degradation of chromosomal DNA into small internucleosomal fragments, evidenced by the formation of a 180-200 bp DNA ladder on agarose gels. FCM analysis showed the peak areas of subdiploid at the increased concentration of Sch B. The results of Western bolt analysis showed that Hsp70 was down-regulated and Caspase-3 was up-regulated, while the activity of Caspases-7, -9 had no significant change. CONCLUSION: Sch B is able to inhibit the proliferation of human hepatoma SMMC-7721 cells and induce apoptosis, which goes through Caspase-3-dependent and Caspase-9-independent pathway accompanied with the down-regulation of Hsp70 protein expression at an early event.


Assuntos
Carcinoma Hepatocelular/metabolismo , Caspases/metabolismo , Proliferação de Células/efeitos dos fármacos , Ciclo-Octanos/farmacologia , Proteínas de Choque Térmico HSP70/metabolismo , Lignanas/farmacologia , Neoplasias Hepáticas/metabolismo , Compostos Policíclicos/farmacologia , Apoptose/efeitos dos fármacos , Western Blotting , Diferenciação Celular , Ciclo-Octanos/química , Regulação para Baixo , Citometria de Fluxo , Humanos , Lignanas/química , Compostos Policíclicos/química , Células Tumorais Cultivadas , Regulação para Cima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA